Tribune News Network
Doha
A study led by Sidra Medicine, a member of Qatar Foundation, has revealed the impact of our immune system and microbiota on our ability to survive colon cancer.
The study, published in Nature Medicine, was conducted in collaboration with main partner, Leiden University Medical Center (LUMC) in the Netherlands. The team analysed various aspects of primary colon cancers, including the characteristics of cancer cells, cancer immune responses and microbiota composition.
They found that a specific composition of bacteria in the tumour and intratumoral immune response were associated with a more favourable prognosis for colon cancer patients.
Core researchers from Sidra Medicine included Dr Wouter Hendrickx from the Functional Cancer Omics lab and Dr Davide Bedognetti, former director of the Human Immunology Division, while LUMC researchers included Dr Jessica Roelands, who was previously a joint PhD student at Sidra Medicine, and Dr Peter J.K. Kuppen, associate professor.
Dr Hendrickx said, “This study challenges the current clinical guidelines on colon cancer, which rely solely on tumour-node-metastasis staging and the presence of mismatch repair deficiency. We validated our previously published ICR gene signature of tumour immune rejection which already associated with survival in other cancer types, and a novel microbiome risk score, which is heavily associated with treatment outcomes and survival rates in our colon cancer cohort.”
By combining the bacterial composition and the score for intratumoral immune response, the team identified a subgroup of patients with colon cancer, with an almost 100 percent survival rate. This score, along with ICR score, could be used as predictive biomarkers in cancer immunotherapy to successfully treat colon cancer patients.
The study showcases the potential of multi-omics profiling and offers promising avenues for microbiota-targeting approaches, such as dietary interventions.
Dr Jessica Roelands, who is also first author of the study, said: “This is one of the best characterised colon cancer cohorts worldwide. We hope this resource will be used by physicians and scientists to accelerate research with the goal to improve the prognosis and cure patients suffering from this disease.”
The study will be extended by adding other layers of data, including spatial transcriptomics, immune phenotyping and methylome analyses. These findings could lead to more targeted treatments for colon cancer patients based on their immune response and microbiota composition.
Dr Khalid Fakhro, chief research officer at Sidra Medicine, said: “This study’s impact is yet another strong example of the application of precision medicine in solving health challenges like colon cancer, which ranks as the third most frequent cause of cancer incidence and the second in mortality.It also validates our ground-breaking research collaborations with partners like Leiden University Medical Center that are changing the course of clinical research, diagnosis and care for patients worldwide.”
The study was based on a grant from the Qatar National Research Fund and Sidra Medicine intramural funding. The brief can be accessed at: https://www.nature.com/articles/s41591-023-02384-7.
